Chimera Research Group

previous arrow
next arrow

May 18th Biotech Update

The sector had been strong and that is nice to see.  It was especially interesting to see the sector strength (and market for that matter) when the Fed is talking.   Usually those are guaranteed red days.  Perhaps the sector is becoming a little more immunized against Fed talk.  Of course, just when you think the […]

May 16th Biotech Update

Last week was an interesting one.  We had a lot of hope with the M&A and the strong reaction to it and then disaster as the market continued its weakness and the sector with it.  We then rallied at the end of the week.  Taking a step back and looking and the week overall it […]

May 10th Biotech Update

This should be it.  The sector has been oversold and very stretched to the downside and was due for a bounce.  Today we finally see some significant M&A and this should trigger a nice multi-day rally.  If this deal cannot move the sector in a meaningful way when it is oversold then I do not […]

May 9th Biotech Update

The sector continues to be a complete mess along with the broader market.  We are at multi-year lows and this move lower has been relentless.  I am sounding like a broken record but this has to see a dead cat bounce at some point.  Of course, the one thing the sector has not done is […]

Mailing List



Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.

The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.

Subscribe to Chimera Research Group and proceed with confidence.

Get Started

Recent Press


Log In

JoinLost Password?